These results led to the suggestion that blocking the degradation of GLP-1 by DPP4 could increase endogenous intact (active) GLP-1 concentrations and enhance its anti-hyperglycemic actions, similar to the way angiotensin-converting enzyme inhibitors are used to treat hypertension. Here, GCG is linked to Hypertension.